Werewolf Therapeutics Inc

Werewolf Therapeutics, Inc. is a biopharmaceutical company developing therapeutics engineered to stimulate the body's immune system to treat cancer and other immune-mediated conditions. Using its proprietary PREDATOR platform, the company designs conditionally activated molecules that stimulate adaptive and innate immunity to address the limitations of conventional proinflammatory immune therapies. Its lead candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule, and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, both for advanced or metastatic solid tumors, with WTX-330 also for lymphoma. Other programs include JZP898, WTX-921, WTX-712, WTX-518, WTX-1011, and WTX-2022. The company was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

HOWL▲2

Werewolf Therapeutics posts Q2 GAAP EPS of $0.08, beating estimates by $0.40

Werewolf Therapeutics reported second-quarter 2026 GAAP earnings per share of $0.08, surpassing analyst expectations by $0.40. Revenue reached $21 million, all from collaboration revenue tied to the sale of its JZP898 program to Jazz Pharmaceuticals Ireland Limited, whereas no collaboration revenue was recorded in the same period last year. Cash and cash equivalents stood at $22 million as of June 30, 2026, down from $46.5 million at the end of March, and the company expects its current operating plan to fund operations into the second quarter of 2027.

HOWL ▲

Seeking Alpha·49dRead more →